Thus, our findings now provide the rationale to do so and pave the way for novel biomarker-driven clinical trials testing an EGFR-TKI plus an Akt inhibitor in appropriately selected EGFR-mutant NSCLC patients with high pAkt tumor expression. This evidence concerns the gene AKT1 and neoplasm.